Abstract 3194
Background
Neoadjuvant chemotherapy (NAC) has been increasingly used for gastric cancer. JCOG1302A investigated whether cT3-4/ N1-3 was a suitable criterion for NAC minimizing the contamination of pStage I. In that study, 77.2% of tumors diagnosed as cT3-4 by a combination of endoscopy and computed tomography (CT) were pT3-4. The role of endoscopic ultrasonography (EUS) or additional options in diagnosis of invasion depth was unclear.
Methods
Using data of JCOG1302A, we evaluated accuracy of endoscopic or CT diagnosis of cT3-4 to detect pT3-4, by comparing positive predictive value (PPV), negative predictive value (NPV), and kappa index (KI) between conventional endoscopy (CE) with and without EUS, CT of 5 mm and 1 mm slice, and CT with and without foaming agent (FA).
Results
Data from 1232 patients enrolled in 53 institutions were analyzed (Table). Overall, there is no remarkable difference in any comparison. More specifically, PPV and KI were slightly higher in CE alone rather than in CE combined with EUS. Although NPV was higher in 1 mm slice CT and CT with FA, PPV was higher in 5 mm slice CT and CT without FA. Table 1 Comparison of PPV, NPV, and KI between CE alone and CE combined with EUS, between 5 mm slice CT and 1 mm slice CT, and between CT without FA and CT with FA.Table: 656P
| CE alone (n = 1232) | CE combined with EUS (n = 91) | |
|---|---|---|
| PPV | 79.2% (76.2-81.9) | 73.7% (60.3-84.5) |
| NPV | 59.2% (54.3-63.9) | 58.8% (40.7-75.4) |
| KI | 0.38 (0.33-0.44) | 0.32 (0.12-0.52) |
| 5 mm slice CT (n = 1042) | 1 mm slice CT (n = 255) | |
| PPV | 77.8% (74.6-80.7) | 75.5% (68.9-81.4) |
| NPV | 62.9% (57.1-68.5) | 71.2% (57.9-82.2) |
| KI | 0.38 (0.32-0.44) | 0.39 (0.28-0.51) |
| CT without FA (n = 840) | CT with FA (n = 368) | |
| PPV | 78.6% (75.1-81.8) | 75.1% (69.5-80.1) |
| NPV | 60.9% (54.4-67.3) | 69.7% (59.7-78.5) |
| KI | 0.38 (0.31-0.44) | 0.40 (0.30-0.50) |
95%CIs are shown in brackets
Conclusions
Additional options such as EUS, 1 mm slice CT, or FA in CT may not improve diagnostic accuracy of invasion depth in resectable advanced gastric cancer.
Clinical trial identification
Legal entity responsible for the study
Japanese Clinical Oncology Group.
Funding
National Cancer Center Research and Development Fund (23-A-16, 23-A-19 and 26-A-4) from the Ministry of Health, National Cancer Center Research and Development Fund from the Ministry of Health, Labour and Welfare.
Editorial Acknowledgement
Disclosure
Y. Sato, J. Mizusawa: Grants: Ministry of Health, Labour and Welfare, Japan, Japan Agency for Medical Research and Development (AMED). K. Nakamura: Grants: Ministry of Health, Labour and Welfare, Japan, Japan Agency for Medical Research and Development (AMED); Fees: Bayer Pharma, Chugai Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract